RNA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.0M
-84.7%
19.6M
+2183.1%
860.0K
-93.1%
12.5M
+224.3%
3.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
3.0M
-84.7%
19.6M
+2183.1%
860.0K
-93.1%
12.5M
+224.3%
3.8M
Operating Expenses
25.6M
-30.6%
36.9M
-85.5%
255.3M
+26.9%
201.3M
+15.0%
175.0M
R&D
15.3M
-7.9%
16.7M
-90.0%
166.6M
+7.5%
154.9M
+12.2%
138.1M
SG&A
10.3M
-49.3%
20.3M
-77.2%
88.7M
+91.5%
46.3M
+25.7%
36.9M
Operating Income
-22618000
-30.9%
-17280000
+93.2%
-254478000
-34.8%
-188806000
-10.3%
-171142000
EBITDA
-22275000
-30.0%
-17129000
+93.2%
-252982000
-34.7%
-187750000
-10.2%
-170328000
Net Income
-20186000
-21.4%
-16633000
+93.0%
-237101000
-35.9%
-174442000
-10.9%
-157315000
EPS (Basic)
$-1.18
-21.6%
$-0.97
+37.0%
$-1.54
-21.3%
$-1.27
-5.0%
$-1.21
EPS (Diluted)
$-1.18
-21.6%
$-0.97
+37.0%
$-1.54
-21.3%
$-1.27
-5.0%
$-1.21
Shares (Diluted)
17.1M
+0.0%
17.1M
-88.9%
154.1M
+11.7%
137.9M
+6.4%
129.6M
Atrium Therapeutics (RNA) โ€” Financials